As Tokyo Regulators Open More To Global Clinical Trial Data, Some Japanese Drug Outfits Move West To Expand
This article was originally published in PharmAsia News
Executive Summary
Leaders of the India-based Veeda Clinical Research said that by placing a bridging study leg in a clinical trial program early on time lags that often exist between regulatory agencies in the West and in Asia can be further reduced. That strategy can also expedite a drug's entry into other markets and thus benefit both patients and the pharmaceutical companies behind the new products
You may also be interested in...
PMDA Cuts Review Lag With West In Half, But Application Lag Shows No Relief For Drug Launches In Japan
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has reduced its drug review lag in half since rolling out a plan two years ago to cut the drug lag, but products launched in the U.S. still hold a two-year head start compared to products launches in Japan, according to new estimates released by Japan's drug regulatory agency
PMDA Cuts Review Lag With West In Half, But Application Lag Shows No Relief For Drug Launches In Japan
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has reduced its drug review lag in half since rolling out a plan two years ago to cut the drug lag, but products launched in the U.S. still hold a two-year head start compared to products launches in Japan, according to new estimates released by Japan's drug regulatory agency
U.S. Private Equity Stake In CMIC Shows Rosy Outlook For Japan's Contract Research Market
TOKYO - U.S. private equity firm Taiyo Pacific Partners secured a 5 percent stake in CMIC, Japan's largest CRO, highlighting the CRO market growth potential in Japan, despite increased focus on R&D outsourcing to China and India